IDEAYA Biosciences, Inc. Operating Cash Flow
IDEAYA Biosciences, Inc. (IDYA) reported Operating Cash Flow of -$163.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$88.21M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$75.17M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$90.50M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $142.21M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$71.10M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$247.58M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$115.22M.
- IDEAYA Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$87.17M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$88.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$163.38M 10-Q · filed 2026-08-04 | -$253.88M derived: sum of 3 quarters · filed 2026-08-04 | -$111.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$75.17M 10-Q · filed 2026-05-05 | -$165.67M derived: sum of 2 quarters · filed 2026-05-05 | -$23.45M derived: sum of 3 quarters · filed 2026-05-05 | -$85.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$90.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $51.72M derived: sum of 2 quarters · filed 2026-02-17 | -$10.76M derived: sum of 3 quarters · filed 2026-08-04 | -$71.10M 10-K · filed 2026-02-17 |
| 2025-09-30 | $142.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $79.74M derived: sum of 2 quarters · filed 2026-08-04 | $19.40M 10-Q · filed 2025-11-04 | -$102.26M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$62.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$122.82M 10-Q · filed 2026-08-04 | -$244.47M derived: sum of 3 quarters · filed 2026-08-04 | -$293.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$60.34M 10-Q · filed 2026-05-05 | -$182.00M derived: sum of 2 quarters · filed 2026-05-05 | -$231.23M derived: sum of 3 quarters · filed 2026-05-05 | -$264.11M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$121.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$170.89M derived: sum of 2 quarters · filed 2026-02-17 | -$203.77M derived: sum of 3 quarters · filed 2026-02-17 | -$247.58M 10-K · filed 2026-02-17 |
| 2024-09-30 | -$49.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$82.12M derived: sum of 2 quarters · filed 2025-11-04 | -$125.93M 10-Q · filed 2025-11-04 | -$149.68M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$32.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$76.69M 10-Q · filed 2025-08-05 | -$100.44M derived: sum of 3 quarters · filed 2026-02-17 | -$130.62M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$43.81M 10-Q · filed 2025-05-06 | -$67.56M derived: sum of 2 quarters · filed 2026-02-17 | -$97.73M derived: sum of 3 quarters · filed 2026-02-17 | -$131.19M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | -$23.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$53.92M derived: sum of 2 quarters · filed 2026-02-17 | -$87.38M derived: sum of 3 quarters · filed 2026-02-17 | -$115.22M 10-K · filed 2026-02-17 |
| 2023-09-30 | -$30.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$63.63M derived: sum of 2 quarters · filed 2024-11-04 | -$91.48M 10-Q · filed 2024-11-04 | -$114.85M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$33.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$61.30M 10-Q · filed 2024-08-06 | -$84.67M derived: sum of 3 quarters · filed 2025-02-18 | -$108.84M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$27.84M 10-Q · filed 2024-05-07 | -$51.21M derived: sum of 2 quarters · filed 2025-02-18 | -$75.38M derived: sum of 3 quarters · filed 2025-02-18 | -$95.37M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$23.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$47.54M derived: sum of 2 quarters · filed 2025-02-18 | -$67.53M derived: sum of 3 quarters · filed 2025-02-18 | -$87.17M 10-K · filed 2025-02-18 |
| 2022-09-30 | -$24.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$44.16M derived: sum of 2 quarters · filed 2023-11-07 | -$63.80M 10-Q · filed 2023-11-07 | -$80.46M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$19.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$39.64M 10-Q · filed 2023-08-10 | -$56.30M derived: sum of 3 quarters · filed 2024-02-20 | -$68.76M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$19.65M 10-Q · filed 2023-05-09 | -$36.30M derived: sum of 2 quarters · filed 2024-02-20 | -$48.77M derived: sum of 3 quarters · filed 2024-02-20 | -$61.70M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$16.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$29.13M derived: sum of 2 quarters · filed 2024-02-20 | -$42.05M derived: sum of 3 quarters · filed 2024-02-20 | -$55.78M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$12.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$25.40M derived: sum of 2 quarters · filed 2022-11-08 | -$39.12M 10-Q · filed 2022-11-08 | -$50.72M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$12.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$26.65M 10-Q · filed 2022-08-15 | -$38.25M derived: sum of 3 quarters · filed 2023-03-07 | $51.96M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | -$13.72M 10-Q · filed 2022-05-10 | -$25.32M derived: sum of 2 quarters · filed 2023-03-07 | $64.89M derived: sum of 3 quarters · filed 2023-03-07 | $51.28M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | -$11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $78.61M derived: sum of 2 quarters · filed 2023-03-07 | $65.01M derived: sum of 3 quarters · filed 2023-03-07 | $55.46M 10-K · filed 2023-03-07 |
| 2020-09-30 | $90.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $76.60M derived: sum of 2 quarters · filed 2021-11-15 | $67.06M 10-Q · filed 2021-11-15 | $58.35M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | -$13.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$23.15M 10-Q · filed 2021-08-10 | -$31.86M derived: sum of 3 quarters · filed 2022-03-18 | -$42.41M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | -$9.54M 10-Q · filed 2021-05-10 | -$18.25M derived: sum of 2 quarters · filed 2022-03-18 | -$28.80M derived: sum of 3 quarters · filed 2022-03-18 | -$39.07M derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | -$8.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$19.26M derived: sum of 2 quarters · filed 2022-03-18 | -$29.53M derived: sum of 3 quarters · filed 2022-03-18 | -$39.31M 10-K · filed 2022-03-18 |
| 2019-09-30 | -$10.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$20.82M derived: sum of 2 quarters · filed 2020-11-12 | -$30.61M 10-Q · filed 2020-11-12 | -$38.08M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | -$10.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$20.06M 10-Q · filed 2020-08-12 | -$27.53M derived: sum of 3 quarters · filed 2021-03-23 | -$36.23M derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | -$9.79M 10-Q · filed 2020-05-12 | -$17.26M derived: sum of 2 quarters · filed 2021-03-23 | -$25.95M derived: sum of 3 quarters · filed 2021-03-23 | |
| 2018-12-31 | -$7.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$16.17M derived: sum of 2 quarters · filed 2021-03-23 | -$27.62M 10-K · filed 2021-03-23 | |
| 2018-09-30 | -$8.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$20.14M 10-Q · filed 2019-11-13 | ||
| 2018-06-30 | -$11.45M 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | -$12.22M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |